Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Non-Current Debt (2016 - 2023)

Historic Non-Current Debt for Ernexa Therapeutics (ERNA) over the last 11 years, with Q1 2023 value amounting to $768000.0.

  • Ernexa Therapeutics' Non-Current Debt changed N/A to $768000.0 in Q1 2023 from the same period last year, while for Mar 2023 it was $768000.0, marking a year-over-year change of. This contributed to the annual value of $1.2 million for FY2022, which is N/A changed from last year.
  • Latest data reveals that Ernexa Therapeutics reported Non-Current Debt of $768000.0 as of Q1 2023.
  • In the past 5 years, Ernexa Therapeutics' Non-Current Debt ranged from a high of $2.5 million in Q1 2019 and a low of $77670.0 during Q1 2021
  • For the 5-year period, Ernexa Therapeutics' Non-Current Debt averaged around $1.3 million, with its median value being $1.4 million (2020).
  • Examining YoY changes over the last 5 years, Ernexa Therapeutics' Non-Current Debt showed a top increase of 1095.62% in 2019 and a maximum decrease of 3325.5% in 2019.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Non-Current Debt stood at $2.0 million in 2019, then crashed by 90.24% to $194000.0 in 2020, then tumbled by 59.96% to $77670.0 in 2021, then skyrocketed by 1452.72% to $1.2 million in 2022, then plummeted by 36.32% to $768000.0 in 2023.
  • Its last three reported values are $768000.0 in Q1 2023, $1.2 million for Q4 2022, and $77670.0 during Q1 2021.